Ascendis Pharma A/S
ASND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.86 | 0.75 | -0.23 | 1.09 |
| FCF Yield | -4.00% | -7.32% | -7.98% | -6.82% |
| EV / EBITDA | -27.56 | -16.45 | -12.41 | -17.12 |
| Quality | ||||
| ROIC | -37.00% | -88.19% | -70.90% | -45.20% |
| Gross Margin | 87.83% | 83.36% | 76.28% | 54.71% |
| Cash Conversion Ratio | 0.81 | 0.97 | 0.85 | 1.09 |
| Growth | ||||
| Revenue 3-Year CAGR | 92.25% | 224.88% | 94.52% | -16.53% |
| Free Cash Flow Growth | 34.52% | 7.92% | -15.46% | -50.76% |
| Safety | ||||
| Net Debt / EBITDA | -1.02 | -0.85 | -0.33 | 0.65 |
| Interest Coverage | -4.26 | -10.34 | -18.31 | -115.52 |
| Efficiency | ||||
| Inventory Turnover | 0.15 | 0.21 | 0.09 | 0.05 |
| Cash Conversion Cycle | 1,809.85 | 989.36 | 976.35 | 1,759.67 |